Biomarkers after stopping treatment may identify at-risk MS patients
November 30, 2023…et al. Neurol Neuroimmunol Neuroinflamm 2023;10:e200167; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC10574823/pdf/NXI-2023-000383.pdf ). The study obtained serum NfL and GFAP levels before and after drug discontinuation in 78 MS patients. Patients were younger than those enrolled in recent discontinuation trials. Median age was 48.5 years, and median disease duration was 12.3 years. All participants had no clinical attacks or MRI activi…